136 related articles for article (PubMed ID: 16525672)
1. Beneficial effects of protein-bound polysaccharide K plus tegafur/uracil in patients with stage II or III colorectal cancer: analysis of immunological parameters.
Ohwada S; Ogawa T; Makita F; Tanahashi Y; Ohya T; Tomizawa N; Satoh Y; Kobayashi I; Izumi M; Takeyoshi I; Hamada K; Minaguchi S; Togo Y; Toshihiko T; Koyama T; Kamio M
Oncol Rep; 2006 Apr; 15(4):861-8. PubMed ID: 16525672
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study.
Ohwada S; Ikeya T; Yokomori T; Kusaba T; Roppongi T; Takahashi T; Nakamura S; Kakinuma S; Iwazaki S; Ishikawa H; Kawate S; Nakajima T; Morishita Y
Br J Cancer; 2004 Mar; 90(5):1003-10. PubMed ID: 14997197
[TBL] [Abstract][Full Text] [Related]
3. PSK may suppress CD57(+) T cells to improve survival of advanced gastric cancer patients.
Akagi J; Baba H
Int J Clin Oncol; 2010 Apr; 15(2):145-52. PubMed ID: 20229169
[TBL] [Abstract][Full Text] [Related]
4. [Subset analysis of preoperative lymphocyte ratio in stage II or III colorectal cancer patients treated with oral tegafur-uracil and protein-bound polysaccharide K].
Totsuka O; Kawate S; Hirai K; Ogawa H; Toya H; Yoshinari D; Sunose Y; Takeyoshi I
Gan To Kagaku Ryoho; 2013 Dec; 40(13):2525-8. PubMed ID: 24335363
[TBL] [Abstract][Full Text] [Related]
5. Prognostic markers for immunochemotherapy using tegafur -uracil (UFT) and protein-bound polysaccharide K (PSK).
Yoshinaga K; Saeki H; Oki E; Morita M; Ikeda T; Sugimachi K; Yamashita Y; Ikegami T; Uchiyama H; Yoshizumi T; Soejima Y; Kawanaka H; Mimori K; Watanabe M; Maehara Y
Fukuoka Igaku Zasshi; 2013 Dec; 104(12):549-58. PubMed ID: 24693683
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of postoperative UFT (Tegafur/Uracil) plus PSK therapies in elderly patients with resected colorectal cancer.
Yoshitani S; Takashima S
Cancer Biother Radiopharm; 2009 Feb; 24(1):35-40. PubMed ID: 19243246
[TBL] [Abstract][Full Text] [Related]
7. Phase III trial comparing UFT + PSK to UFT + LV in stage IIB, III colorectal cancer (MCSGO-CCTG).
Miyake Y; Nishimura J; Kato T; Ikeda M; Tsujie M; Hata T; Takemasa I; Mizushima T; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M;
Surg Today; 2018 Jan; 48(1):66-72. PubMed ID: 28634730
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant therapy with protein-bound polysaccharide K and tegafur uracil in patients with stage II or III colorectal cancer: randomized, controlled trial.
Ohwada S; Kawate S; Ikeya T; Yokomori T; Kusaba T; Roppongi T; Takahashi T; Nakamura S; Kawashima Y; Nakajima T; Morishita Y;
Dis Colon Rectum; 2003 Aug; 46(8):1060-8. PubMed ID: 12907900
[TBL] [Abstract][Full Text] [Related]
9. Significance of postoperative adjuvant immunochemotherapy after curative resection of colorectal cancers: identification of responders incorporating the age factor.
Munemoto Y; Iida Y; Ohata K; Saito H; Fujisawa K; Kasahara Y; Mitsui T; Asada Y; Miura S
Oncol Rep; 2004 Mar; 11(3):623-35. PubMed ID: 14767513
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase III trial comparing surgery alone to UFT + PSK for stage II rectal cancer (JFMC38 trial).
Okuno K; Aoyama T; Oba K; Yokoyama N; Matsuhashi N; Kunieda K; Nishimura Y; Akamatsu H; Kobatake T; Morita S; Yoshikawa T; Sakamoto J; Saji S
Cancer Chemother Pharmacol; 2018 Jan; 81(1):65-71. PubMed ID: 29094178
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of immunochemotherapy with PSK, a protein-bound polysaccharide, in colorectal cancer and changes of tumor marker.
Kudo S; Tanaka J; Kashida H; Tamegai Y; Endo S; Yamano HO
Oncol Rep; 2002; 9(3):635-8. PubMed ID: 11956642
[TBL] [Abstract][Full Text] [Related]
12. An anticancer drug sensitivity test to determine the effectiveness of UFT as postoperative adjuvant chemotherapy for patients with stage III colorectal cancer.
Isogai A; Nagaya M; Matsuoka H; Watanabe T; Tsukikawa S; Kubota S
Surgery; 2007 Nov; 142(5):741-8. PubMed ID: 17981195
[TBL] [Abstract][Full Text] [Related]
13. Significance of postoperative adjuvant immunochemotherapy after curative resection of colorectal cancers: Association between host or tumor factors and survival.
Munemoto Y; Iida Y; Abe J; Saito H; Fujisawa K; Kasahara Y; Mitsui T; Asada Y; Miura S
Int J Oncol; 2002 Feb; 20(2):403-11. PubMed ID: 11788909
[TBL] [Abstract][Full Text] [Related]
14. The association between neutropenia and prognosis in stage III colorectal cancer patients receiving adjuvant chemotherapy.
Sunaga T; Suzuki S; Kogo M; Kurihara T; Kaji S; Koike N; Harada N; Suzuki M; Kiuchi Y
Eur J Cancer Care (Engl); 2014 May; 23(3):394-400. PubMed ID: 24033646
[TBL] [Abstract][Full Text] [Related]
15. Preoperative CEA and PPD values as prognostic factors for immunochemotherapy using PSK and 5-FU.
Takahashi Y; Mai M; Nakazato H
Anticancer Res; 2005; 25(2B):1377-84. PubMed ID: 15865094
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of oral tegafur-uracil as maintenance therapy following intravenous 5-fluorouracil chemotherapy in stage III colon cancer.
Hong KD; Lee SI; Moon HY
Hepatogastroenterology; 2012; 59(113):104-7. PubMed ID: 22251527
[TBL] [Abstract][Full Text] [Related]
17. Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer.
Sugimachi K; Maehara Y; Ogawa M; Kakegawa T; Tomita M
Cancer Chemother Pharmacol; 1997; 40(3):233-8. PubMed ID: 9219507
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer.
Alliot C
Br J Cancer; 2004 Sep; 91(6):1220-1; author reply 1221-3. PubMed ID: 15305190
[No Abstract] [Full Text] [Related]
19. [Administration of polysaccharide K (PSK) for stage III colorectal cancer in clinical practice].
Ishibashi K; Ishiguro T; Kuwabara K; Ohsawa T; Okada N; Miyazaki T; Yokoyama M; Matsuki M; Ishida H
Gan To Kagaku Ryoho; 2008 Nov; 35(12):2283-5. PubMed ID: 19106597
[TBL] [Abstract][Full Text] [Related]
20. Protein-bound polysaccharide increases survival in resected gastric cancer cases stratified with a preoperative granulocyte and lymphocyte count.
Toge T; Yamaguchi Y
Oncol Rep; 2000; 7(5):1157-61. PubMed ID: 10948356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
